Table 1.
Gene set namea | Size | Enrichment scoreb | FDR q-value |
---|---|---|---|
KEGG_PARKINSONS_DISEASEc | 87 | 0.77 | <0.0001 |
KEGG_OXIDATIVE_PHOSPHORYLATION | 89 | 0.77 | <0.0001 |
KEGG_HUNTINGTONS_DISEASEc | 129 | 0.67 | <0.0001 |
KEGG_PEROXISOME | 57 | 0.74 | <0.0001 |
KEGG_ALZHEIMERS_DISEASEc | 121 | 0.64 | <0.0001 |
KEGG_CITRATE_CYCLE_TCA_CYCLE | 25 | 0.82 | <0.0001 |
KEGG_FATTY_ACID_METABOLISM | 35 | 0.72 | 0.0001 |
KEGG_PPAR_SIGNALING_PATHWAY | 54 | 0.67 | 0.0001 |
KEGG_VALINE_LEUCINE_AND_ISOLEUCINE_DEGRADATION | 40 | 0.65 | 0.001 |
KEGG_FRUCTOSE_AND_MANNOSE_METABOLISM | 22 | 0.72 | 0.0026 |
aLin−CD29+CD34+Sca-1+ cells were cultured in adipogenic media ± cPGI2 for 8 days. RNA expression profiling was performed with Illumina beadchip arrays (n = 3). Global expression profiles (cPGI2 vs. Control) were subjected to gene set enrichment analysis (GSEA) with the KEGG pathway gene set collection. Gene sets were ranked by the False Discovery Rate (FDR) q-value reflecting significance.
bMaximum of the corresponding enrichment score curve.
cThe indicated gene sets are overlapping >50% with the KEGG_OXIDATIVE_PHOSPHORYLATION gene set.